Novartis Shares Fall as Entresto Sales Weaken

Why It Matters

The patent cliff threatens Novartis' core earnings, making its pipeline and recent acquisitions critical to sustaining long‑term growth and investor confidence.

Key Takeaways

• Entresto sales dropped 46% to $1.3 billion after US patent loss
• Overall Q1 net sales fell 5% to $13.1 billion, missing forecasts
• Growth drugs Kisqali, Pluvicto, Kesimpta drove double‑digit revenue gains
• Novartis models $4 billion revenue hit from patent expirations this year
• Acquisitions total $17 billion (Avidity, Synnovation, Excellergy) to bolster pipeline

Pulse Analysis

Novartis’ first‑quarter results underscore the accelerating impact of the pharmaceutical patent cliff. The loss of market exclusivity for Entresto, once a $1.3 billion revenue engine, triggered a 46% sales decline and contributed to a broader 5% revenue contraction. Combined with generic pressure on Tasigna and Promacta, the company now anticipates a $4 billion hit to its top line this year, a figure that will test its ability to maintain profit margins while navigating the low‑single‑digit growth environment expected for the remainder of 2024.

Despite the headwinds, Novartis is leveraging its diversified portfolio to offset the erosion. Oncology and specialty drugs such as Kisqali, which surged 55% to $1.52 billion, and the radiopharmaceutical Pluvicto, up 70% to $642 million, illustrate the firm’s shift toward higher‑margin, growth‑driven segments. Multiple‑sclerosis therapy Kesimpta also posted a 26% increase, reinforcing the strategic focus on chronic‑disease treatments that are less vulnerable to rapid generic entry. Moreover, promising phase‑3 data for remibrutinib and ongoing pipeline advancements signal potential new revenue streams beyond the current cliff.

To reinforce its long‑term outlook, Novartis has embarked on a $17 billion acquisition spree, closing a $12 billion deal for Avidity and adding late‑stage assets from Synnovation and Excellergy. These purchases aim to replenish the pipeline with neuromuscular, breast‑cancer, and food‑allergy candidates, mitigating future patent expirations. However, the looming MFN pricing policy could compress U.S. Medicaid margins, adding another layer of fiscal pressure. Investors will be watching how effectively the company integrates these assets and translates pipeline momentum into sustainable earnings growth.